[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SLC35A1

Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane; Multi-pass membrane protein.
Domain PF04142 Nucleotide-sugar transporter
Function

Transports CMP-sialic acid from the cytosol into Golgi vesicles where glycosyltransferases function.

> Gene Ontology
 
Biological Process GO:0006818 hydrogen transport
GO:0008643 carbohydrate transport
GO:0015672 monovalent inorganic cation transport
GO:0015780 nucleotide-sugar transport
GO:0015781 pyrimidine nucleotide-sugar transport
GO:0015782 CMP-N-acetylneuraminate transport
GO:0015931 nucleobase-containing compound transport
GO:0015992 proton transport
GO:1901264 carbohydrate derivative transport
Molecular Function GO:0005338 nucleotide-sugar transmembrane transporter activity
GO:0005351 sugar:proton symporter activity
GO:0005402 cation:sugar symporter activity
GO:0005456 CMP-N-acetylneuraminate transmembrane transporter activity
GO:0015144 carbohydrate transmembrane transporter activity
GO:0015165 pyrimidine nucleotide-sugar transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015295 solute:proton symporter activity
GO:0015932 nucleobase-containing compound transmembrane transporter activity
GO:0022804 active transmembrane transporter activity
GO:0051119 sugar transmembrane transporter activity
GO:1901476 carbohydrate transporter activity
GO:1901505 carbohydrate derivative transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-4085001: Sialic acid metabolism
R-HSA-446219: Synthesis of substrates in N-glycan biosythesis
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-727802: Transport of nucleotide sugars
R-HSA-425397: Transport of vitamins, nucleosides, and related molecules
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC35A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC35A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.55; FDR: 0.00722 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC35A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1870.473
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0690.971
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3820.757
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0810.916
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2880.425
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.4380.44
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0930.788
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0011
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2610.871
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1130.925
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8130.648
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.080.264
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC35A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC35A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC35A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC35A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC35A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC35A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC35A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC35A1
Namesolute carrier family 35 (CMP-sialic acid transporter), member A1
Aliases CMPST; solute carrier family 35 (UDP-galactose transporter), member 1; CDG2F; CMP-SA-Tr; CMP-Sia-Tr; mutated ......
Chromosomal Location6q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC35A1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.